Victory Capital Management Inc. Buys 51,671 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Victory Capital Management Inc. lifted its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 300.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 68,871 shares of the biopharmaceutical company's stock after purchasing an additional 51,671 shares during the period. Victory Capital Management Inc.'s holdings in Ocular Therapeutix were worth $588,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. boosted its position in shares of Ocular Therapeutix by 1.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company's stock valued at $9,663,000 after purchasing an additional 21,025 shares in the last quarter. Hussman Strategic Advisors Inc. purchased a new position in Ocular Therapeutix during the fourth quarter valued at $897,000. New York State Common Retirement Fund boosted its holdings in shares of Ocular Therapeutix by 18.4% during the 4th quarter. New York State Common Retirement Fund now owns 98,097 shares of the biopharmaceutical company's stock valued at $838,000 after buying an additional 15,239 shares in the last quarter. Truist Financial Corp purchased a new stake in shares of Ocular Therapeutix in the 4th quarter worth about $427,000. Finally, Palumbo Wealth Management LLC bought a new position in shares of Ocular Therapeutix in the 4th quarter worth about $100,000. Institutional investors own 59.21% of the company's stock.

Ocular Therapeutix Stock Down 1.2 %

OCUL traded down $0.09 during trading on Tuesday, hitting $7.53. 1,229,481 shares of the company's stock traded hands, compared to its average volume of 1,509,038. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -5.70 and a beta of 1.34. The company's 50 day simple moving average is $7.56 and its two-hundred day simple moving average is $8.78. Ocular Therapeutix, Inc. has a 12-month low of $4.06 and a 12-month high of $11.78. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19.

Remove Ads

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The business had revenue of $17.08 million for the quarter, compared to analysts' expectations of $16.89 million. Analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on OCUL shares. HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. JMP Securities set a $19.00 price target on Ocular Therapeutix in a research report on Tuesday, March 4th. Needham & Company LLC began coverage on Ocular Therapeutix in a research report on Tuesday, March 11th. They set a "buy" rating and a $15.00 price objective for the company. Finally, Royal Bank of Canada assumed coverage on Ocular Therapeutix in a research note on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $16.38.

Insider Transactions at Ocular Therapeutix

In other news, insider Donald Notman sold 11,119 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total transaction of $86,839.39. Following the transaction, the insider now directly owns 193,444 shares of the company's stock, valued at $1,510,797.64. This represents a 5.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Pravin Dugel sold 21,475 shares of the business's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the sale, the insider now owns 3,520,318 shares of the company's stock, valued at approximately $24,184,584.66. This represents a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,895 shares of company stock worth $283,772 over the last three months. 3.50% of the stock is currently owned by company insiders.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.